Mustafa Erdem Arslan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mustafa Erdem Arslan has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Hwajeong Lee
Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, USA
9 shared publications - Hua Li
Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA
5 shared publications - Dipti M. Karamchandani
Department of Pathology UT Southwestern Medical Center Dallas TX USA
3 shared publications - Edward C. Lee
Department of Surgery, Albany Medical Center, Albany, NY, USA
3 shared publications - Adam Petchers
Department of Surgery, Albany Medical Center, Albany, NY, USA
2 shared publications - Ankesh Nigam
Department of Surgery, Albany Medical Center, Albany, NY, USA
2 shared publications
Latest Publications
- 10 June 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51  (1) , 50-62
CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort
Objectives Various mutations in hepatocellular carcinoma (HCC) carry prognostic implications. The objective of this study is to assess CT and MRI imaging features associated with Catenin Beta-1 (CTNNB1) mutation in HCC. Methods This retrospective, IRB- approved multi-reader, single-center study included treatment-naive, pathologic-proven HCC that underwent contrast-enhanced CT, MRI or both, with subsequent targeted tumor sequencing test. Preoperative CT and MRI were reviewed for the Liver Imaging Reporting and Data System (LI-RADS, LR) features and prognostic imaging features. Fisher’s exact test and multiple testing adjustment were used to assess the association of imaging features and CTNNB1 mutation status. Results Of the 160 HCCs included (median age 69 [IQR: 62, 75], 125 men), 58 (36%) had CTNNB1 mutation. Compared to wildtype, CTNNB1-mutated HCCs were more likely to be present as solitary lesion (CT: 26/43[60%] vs. 31/80 [40%], p = 0.024), have mosaic appearance (MRI: 9/34[26%] vs. 3/68[4.4%], p = 0.002), blood products in mass (CT: 7/43[16%] vs. 2/80[2.5%], p = 0.009; MRI: 12/34[35%] vs. 8/68[12%], p = 0.008), necrosis (CT: 16/43[37%] vs. 14/80[18]%, p = 0.026), intralesional arteries (CT: 26/43[60%] vs. 32/80[40%], p = 0.038). A subgroup of 98 high risk patients (hepatitis B, morphologic cirrhosis) were assigned LI-RADS categorization; majority of patients were assigned LR-5 (CT: 15/25[60%] vs. 21/52[40%]; MRI: 10/18[56%] vs. 19/44[43%]). No feature was significantly associated with CTNNB1 mutation status after multiple testing adjustment. Conclusion Compared to wildtype, CTNNB1-mutated HCCs are more likely to appear as solitary masses with mosaic, heterogeneous appearance containing blood products, necrosis and intralesional arteries. Majority of CTNNB1-mutated tumors were categorized as LR-5 in a subgroup of high risk patients. No imaging feature independently predicted CTNNB1-mutated HCCs.
- 10 June 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51  (1) , 50-62
CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort
Objectives Various mutations in hepatocellular carcinoma (HCC) carry prognostic implications. The objective of this study is to assess CT and MRI imaging features associated with Catenin Beta-1 (CTNNB1) mutation in HCC. Methods This retrospective, IRB- approved multi-reader, single-center study included treatment-naive, pathologic-proven HCC that underwent contrast-enhanced CT, MRI or both, with subsequent targeted tumor sequencing test. Preoperative CT and MRI were reviewed for the Liver Imaging Reporting and Data System (LI-RADS, LR) features and prognostic imaging features. Fisher’s exact test and multiple testing adjustment were used to assess the association of imaging features and CTNNB1 mutation status. Results Of the 160 HCCs included (median age 69 [IQR: 62, 75], 125 men), 58 (36%) had CTNNB1 mutation. Compared to wildtype, CTNNB1-mutated HCCs were more likely to be present as solitary lesion (CT: 26/43[60%] vs. 31/80 [40%], p = 0.024), have mosaic appearance (MRI: 9/34[26%] vs. 3/68[4.4%], p = 0.002), blood products in mass (CT: 7/43[16%] vs. 2/80[2.5%], p = 0.009; MRI: 12/34[35%] vs. 8/68[12%], p = 0.008), necrosis (CT: 16/43[37%] vs. 14/80[18]%, p = 0.026), intralesional arteries (CT: 26/43[60%] vs. 32/80[40%], p = 0.038). A subgroup of 98 high risk patients (hepatitis B, morphologic cirrhosis) were assigned LI-RADS categorization; majority of patients were assigned LR-5 (CT: 15/25[60%] vs. 21/52[40%]; MRI: 10/18[56%] vs. 19/44[43%]). No feature was significantly associated with CTNNB1 mutation status after multiple testing adjustment. Conclusion Compared to wildtype, CTNNB1-mutated HCCs are more likely to appear as solitary masses with mosaic, heterogeneous appearance containing blood products, necrosis and intralesional arteries. Majority of CTNNB1-mutated tumors were categorized as LR-5 in a subgroup of high risk patients. No imaging feature independently predicted CTNNB1-mutated HCCs.
- Open Access
- 16 February 2023
- Published by MDPI AG in Current Oncology
- Vol. 30  (2) , 2388-2404
Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine
Immunotherapy has remained at the vanguard of promising cancer therapeutic regimens due to its exceptionally high specificity for tumor cells and potential for significantly improved treatment-associated quality of life compared to other therapeutic approaches such as surgery and chemoradiation. This is especially true in the digestive system, where high rates of mutation give rise to a host of targetable tumor-specific antigens. Many patients, however, do not exhibit measurable improvements under immunotherapy due to intrinsic or acquired resistance, making predictive biomarkers necessary to determine which patients will benefit from this line of treatment. Many of these biomarkers are assessed empirically by pathologists according to nuanced scoring criteria and algorithms. This review serves to inform clinicians and pathologists of extant and promising upcoming biomarkers predictive of immunotherapeutic efficacy among digestive system malignancies and the ancillary testing required for interpretation by pathologists according to tumor site of origin.
- 16 February 2023
- Published by MDPI AG in Current Oncology
- Vol. 30  (2) , 2388-2404
Open AccessTumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine
Immunotherapy has remained at the vanguard of promising cancer therapeutic regimens due to its exceptionally high specificity for tumor cells and potential for significantly improved treatment-associated quality of life compared to other therapeutic approaches such as surgery and chemoradiation. This is especially true in the digestive system, where high rates of mutation give rise to a host of targetable tumor-specific antigens. Many patients, however, do not exhibit measurable improvements under immunotherapy due to intrinsic or acquired resistance, making predictive biomarkers necessary to determine which patients will benefit from this line of treatment. Many of these biomarkers are assessed empirically by pathologists according to nuanced scoring criteria and algorithms. This review serves to inform clinicians and pathologists of extant and promising upcoming biomarkers predictive of immunotherapeutic efficacy among digestive system malignancies and the ancillary testing required for interpretation by pathologists according to tumor site of origin.
- Open Access
- 1 February 2023
- Published by Elsevier in Academic Pathology
- Vol. 10  (1) , 100063
Diagnostic yield and repeat biopsies in rectal and nonrectal colorectal adenocarcinoma: Are we hedging on rectal biopsies?
- 1 February 2023
- Published by Elsevier in Academic Pathology
- Vol. 10  (1) , 100063
Open AccessDiagnostic yield and repeat biopsies in rectal and nonrectal colorectal adenocarcinoma: Are we hedging on rectal biopsies?
- Open Access
- 4 July 2022
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56  (5) , 239-248
Inflammation and tissue remodeling contribute to fibrogenesis in stricturing Crohn’s disease: image processing and analysis study
Background: Inflammation and structural remodeling may contribute to fibrogenesis in Crohn’s disease (CD). We quantified the immunoexpression of calretinin, CD34, and calprotectin as a surrogate for mucosal innervation, telocytes (interstitial cells playing a role in networking), and inflammation, respectively, and correlated them with bowel alterations in stricturing CD.Methods: Primary resection specimens for ileal CD (n = 44, 31 stricturing CD, 13 inflammatory CD) were identified. Left-sided ulcerative colitis and trauma cases were used as controls. Proximal and distal margin and middle (diseased) sections were stained for calretinin, CD34, and calprotectin. Microscopic images were captured from the mucosa (calretinin), submucosa (calprotectin), and myenteric plexus (CD34), and the immunostaining was quantified using image processing and analysis. Bowel thickness at the corresponding sections were measured and correlated with the amount of immunoexpression.Results: A total of 2,037 images were analyzed. In stricturing CD, submucosal alteration/thickening at the stricture site correlated with calprotectin staining and inversely correlated with calretinin staining at the proximal margin. Muscularis propria alteration/thickening at the stricture site correlated with mucosal calretinin staining at the proximal margin. Submucosal alteration/thickening at the proximal margin correlated with calretinin and CD34 staining at the proximal margin and inversely correlated with CD34 staining at the stricture site. Calretinin immunostaining at the distal margin was significantly higher in stricturing CD than the controls.Conclusions: Inflammation and tissue remodeling appear to contribute to fibrogenesis in stricturing CD. Increased mucosal calretinin immunostaining distal to the diseased segment could be helpful in diagnosing CD in the right clinical context.
- 4 July 2022
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56  (5) , 239-248
Open AccessInflammation and tissue remodeling contribute to fibrogenesis in stricturing Crohn’s disease: image processing and analysis study
Background: Inflammation and structural remodeling may contribute to fibrogenesis in Crohn’s disease (CD). We quantified the immunoexpression of calretinin, CD34, and calprotectin as a surrogate for mucosal innervation, telocytes (interstitial cells playing a role in networking), and inflammation, respectively, and correlated them with bowel alterations in stricturing CD.Methods: Primary resection specimens for ileal CD (n = 44, 31 stricturing CD, 13 inflammatory CD) were identified. Left-sided ulcerative colitis and trauma cases were used as controls. Proximal and distal margin and middle (diseased) sections were stained for calretinin, CD34, and calprotectin. Microscopic images were captured from the mucosa (calretinin), submucosa (calprotectin), and myenteric plexus (CD34), and the immunostaining was quantified using image processing and analysis. Bowel thickness at the corresponding sections were measured and correlated with the amount of immunoexpression.Results: A total of 2,037 images were analyzed. In stricturing CD, submucosal alteration/thickening at the stricture site correlated with calprotectin staining and inversely correlated with calretinin staining at the proximal margin. Muscularis propria alteration/thickening at the stricture site correlated with mucosal calretinin staining at the proximal margin. Submucosal alteration/thickening at the proximal margin correlated with calretinin and CD34 staining at the proximal margin and inversely correlated with CD34 staining at the stricture site. Calretinin immunostaining at the distal margin was significantly higher in stricturing CD than the controls.Conclusions: Inflammation and tissue remodeling appear to contribute to fibrogenesis in stricturing CD. Increased mucosal calretinin immunostaining distal to the diseased segment could be helpful in diagnosing CD in the right clinical context.
- Open Access
- 1 January 2022
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 10
Scleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy
Systemic sclerosis with negative serology, particularly that complicated by scleroderma renal crisis (SRC), is rarely encountered. We describe a patient with seronegative systemic sclerosis who developed acute kidney injury, proteinuria, and hypertensive emergency following motor vehicle-related trauma and in the setting of nonsteroidal anti-inflammatory drug use. Findings on physical examination, imaging, and skin biopsy led to a clinical diagnosis of scleroderma, despite the lack of supportive laboratory data. IgG lambda paraproteinemia was detected on workup. Bone marrow biopsy showed plasmacytosis and trace lambda-restricted plasma cells consistent with monoclonal gammopathy of undetermined significance. Chemotherapy was initially started given concern for myeloma with cast nephropathy but was later stopped after a kidney biopsy revealed thrombotic microangiopathy (TMA). The SRC associated with TMA was ultimately diagnosed, though atypical hemolytic uremic syndrome (aHUS) induced perhaps by monoclonal gammopathy or hypertension was also possible. Captopril and eculizumab were initiated for SRC and aHUS, respectively. Despite therapy, renal function did not recover, and the patient required hemodialysis indefinitely. This case highlights clinical features common to both SRC and aHUS as well as points out a few ways to differentiate between them.
- 1 January 2022
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 10
Open AccessScleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy
Systemic sclerosis with negative serology, particularly that complicated by scleroderma renal crisis (SRC), is rarely encountered. We describe a patient with seronegative systemic sclerosis who developed acute kidney injury, proteinuria, and hypertensive emergency following motor vehicle-related trauma and in the setting of nonsteroidal anti-inflammatory drug use. Findings on physical examination, imaging, and skin biopsy led to a clinical diagnosis of scleroderma, despite the lack of supportive laboratory data. IgG lambda paraproteinemia was detected on workup. Bone marrow biopsy showed plasmacytosis and trace lambda-restricted plasma cells consistent with monoclonal gammopathy of undetermined significance. Chemotherapy was initially started given concern for myeloma with cast nephropathy but was later stopped after a kidney biopsy revealed thrombotic microangiopathy (TMA). The SRC associated with TMA was ultimately diagnosed, though atypical hemolytic uremic syndrome (aHUS) induced perhaps by monoclonal gammopathy or hypertension was also possible. Captopril and eculizumab were initiated for SRC and aHUS, respectively. Despite therapy, renal function did not recover, and the patient required hemodialysis indefinitely. This case highlights clinical features common to both SRC and aHUS as well as points out a few ways to differentiate between them.
- 1 December 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 222  (6) , 1196-1197
The removal of ectopic pancreas to prevent carcinoma development
- 1 December 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 222  (6) , 1196-1197
The removal of ectopic pancreas to prevent carcinoma development
- Open Access
- 7 June 2021
- Published by MDPI AG in Dermatopathology
- Vol. 8  (2) , 190-201
Concurrent Adjacent Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia without Simultaneous Merkel Cell Polyomavirus Detection: A Case Series
Background: The association between Merkel cell carcinoma (MCC) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) is well established in the literature. A majority of MCCs are known to be associated with Merkel cell carcinoma polyomavirus (MCPyV), which is postulated to be a possible causative agent linking these two entities. We aim to identify the presence of MCPyV in patients with concurrent adjacent MCC and CLL/SLL. Methods: Archived pathology materials of three cutaneous or surgical excisions with concurrent MCC and CLL/SLL were reviewed. Additional 12-µm sections from paraffin-embedded tissue of these resections were matched with original hematoxylin and eosin-stained slides and used to extract foci from each tumor separately. DNA was extracted from these tissues, and polymerase chain reaction (PCR), utilizing a primer set within a highly conserved “small T” viral DNA region, was done to detect MCPyV. Results: Out of 140 cases of cutaneous or surgical excisions with MCC identified in our electronic medical records (EMR), three had coexisting neighboring CLL/SLL in the same resection specimen. In one case out of three, MCPyV was detected in MCC but not in CLL/SLL. The remaining two cases showed no detection of MCPyV in either MCC or CLL/SLL. Conclusion: MCPyV was not concurrently associated with adjacent MCC and CLL/SLL, indicating that it is not driving simultaneous tumorigenesis, at least in a subset of these cases.
- 7 June 2021
- Published by MDPI AG in Dermatopathology
- Vol. 8  (2) , 190-201
Open AccessConcurrent Adjacent Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia without Simultaneous Merkel Cell Polyomavirus Detection: A Case Series
Background: The association between Merkel cell carcinoma (MCC) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) is well established in the literature. A majority of MCCs are known to be associated with Merkel cell carcinoma polyomavirus (MCPyV), which is postulated to be a possible causative agent linking these two entities. We aim to identify the presence of MCPyV in patients with concurrent adjacent MCC and CLL/SLL. Methods: Archived pathology materials of three cutaneous or surgical excisions with concurrent MCC and CLL/SLL were reviewed. Additional 12-µm sections from paraffin-embedded tissue of these resections were matched with original hematoxylin and eosin-stained slides and used to extract foci from each tumor separately. DNA was extracted from these tissues, and polymerase chain reaction (PCR), utilizing a primer set within a highly conserved “small T” viral DNA region, was done to detect MCPyV. Results: Out of 140 cases of cutaneous or surgical excisions with MCC identified in our electronic medical records (EMR), three had coexisting neighboring CLL/SLL in the same resection specimen. In one case out of three, MCPyV was detected in MCC but not in CLL/SLL. The remaining two cases showed no detection of MCPyV in either MCC or CLL/SLL. Conclusion: MCPyV was not concurrently associated with adjacent MCC and CLL/SLL, indicating that it is not driving simultaneous tumorigenesis, at least in a subset of these cases.
- 7 April 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14  (4) , e241265
Early onset calciphylaxis following acute kidney injury secondary to anti-glomerular basement membrane antibody disease
Calciphylaxis is commonly associated with end-stage renal disease (ESRD) and renal transplant. We present a rare case of early onset calciphylaxis in a patient presenting with acute kidney injury (AKI) secondary to anti-glomerular basement membrane (anti-GBM) antibody disease. A 65-year-old obese Caucasian woman with type 2 diabetes mellitus and hypertension presented with a 1-month history of painless gross haematuria and worsening lower extremity oedema. Laboratory results indicated AKI and nephrotic-range proteinuria. Anti-glomerular antibodies were elevated. Renal biopsy revealed focal crescentic glomerulonephritis with linear capillary immunoglobulin G staining consistent with anti-GBM antibody disease. She was treated with haemodialysis, plasmapheresis, steroids, bumetanide and cyclophosphamide. Two months later, she developed necrotic lesions on bilateral thighs. Wound biopsy was consistent with calciphylaxis. This case highlights that calciphylaxis, usually seen in patients with chronic kidney disease or ESRD, can manifest in patients with AKI as well.
- 7 April 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14  (4) , e241265
Early onset calciphylaxis following acute kidney injury secondary to anti-glomerular basement membrane antibody disease
Calciphylaxis is commonly associated with end-stage renal disease (ESRD) and renal transplant. We present a rare case of early onset calciphylaxis in a patient presenting with acute kidney injury (AKI) secondary to anti-glomerular basement membrane (anti-GBM) antibody disease. A 65-year-old obese Caucasian woman with type 2 diabetes mellitus and hypertension presented with a 1-month history of painless gross haematuria and worsening lower extremity oedema. Laboratory results indicated AKI and nephrotic-range proteinuria. Anti-glomerular antibodies were elevated. Renal biopsy revealed focal crescentic glomerulonephritis with linear capillary immunoglobulin G staining consistent with anti-GBM antibody disease. She was treated with haemodialysis, plasmapheresis, steroids, bumetanide and cyclophosphamide. Two months later, she developed necrotic lesions on bilateral thighs. Wound biopsy was consistent with calciphylaxis. This case highlights that calciphylaxis, usually seen in patients with chronic kidney disease or ESRD, can manifest in patients with AKI as well.
- 1 April 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 220, 153389
Pyloric gland metaplasia: Potential histologic predictor of severe pouch disease including Crohn’s disease of the pouch in ulcerative colitis
- 1 April 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 220, 153389
Pyloric gland metaplasia: Potential histologic predictor of severe pouch disease including Crohn’s disease of the pouch in ulcerative colitis